HF with mildly reduced EF is gone, stages are updated, and new classifications for medical and interventional therapies are ...

Investigators stressed that the method is simple, doesn’t require ultrasound, and can be done with existing cath lab ...

CRF ® is committed to igniting the next wave of innovation in research and education that will help docto ...

The latest UDMI aims to align classifications with pathology and clinical practice, bringing numerous changes to the 2018 ...

Asymptomatic patients will now be covered and more flexibility has been given to heart teams for individualizing patient care ...

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.

The data “give you pause” when considering closure, especially for women who can tolerate DOACs, Christine Albert says.

It’s unlikely a lipid-lowering agent can directly reduce infection or malignancy, but some argue it could stop a domino ...

SHASTA-3/4 trial data show plozasiran, like olezarsen, can drastically lower triglycerides and the risk of acute pancreatitis ...

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...

The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.